Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate.
Knudsen
L S
LS
Ostergaard
M
M
Baslund
B
B
Narvestad
E
E
Petersen
J
J
Nielsen
H J
HJ
Ejbjerg
B J
BJ
Szkudlarek
M
M
Johansen
J S
JS
D054392:Adipokines; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy; D000071451:Chitinase-3-Like Protein 1; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D000069285:Infliximab; D015850:Interleukin-6 / Q000097:blood*; D037102:Lectins; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D011859:Radiography; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D054392:Adipokines; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D006023:Glycoproteins; D015850:Interleukin-6; D037102:Lectins; D042461:Vascular Endothelial Growth Factor A; D000069285:Infliximab; D008727:Methotrexate